Voltar
Revisão Acesso aberto Revisado por pares
BIBTEX RIS

The echinocandins: three useful choices or three too many?

2009; Elsevier BV; Volume: 35; Issue: 1 Linguagem: Inglês

10.1016/j.ijantimicag.2009.09.011

ISSN

1872-7913

Autores

Abhijit M. Bal,

Tópico(s)

Fungal Biology and Applications

Resumo

Echinocandins act by inhibiting 1,3-beta-D-glucan synthesis in the fungal cell wall. The three licensed agents in this class, namely anidulafungin, caspofungin and micafungin, have a favourable pharmacological profile. These agents are narrow spectrum with clinically relevant activity against Candida and Aspergillus spp. Several trials have established the non-inferiority of these agents over existing agents in the treatment of invasive fungal infections. Caspofungin is also licensed for empirical antifungal therapy of presumed fungal infections in patients with febrile neutropenia. This paper reviews the literature on echinocandins.

Referência(s)